Please login to the form below

siponimod

This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

S1P receptor modulator franchise based on Gilenya(fingolimod) and recently-launched follow-up Mayzent(siponimod), which for now is approved for secondary progressive forms of MS only.

Latest news

Merck takes evobrutinib for MS into phase 3, on mixed data

It will also have to contend with newer drugs like Roche’s fast-growing Ocrevus(ocrelizumab), Novartis’ Mayzent(siponimod) and potentially Biogen’s Tecfidera follow-up diroximel fumarate(BIIB098).
Novartis sees five new $1bn-plus launches in next two years

That includes Mayzent (siponimod) for secondary progressive multiple sclerosis – approved by the FDA in March – as well as gene therapy Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy, brolucizumab for age-related
Roche and NHS England hail pricing deal on MS drug Ocrevus

A major new competitor in this segment is Novartis’ new oral treatment Mayzent, (siponimod) which has just gained US approval for relapsing/remitting disease and also the first approval for over
Celgene hopes for second time lucky for ozanimod FDA filing

sales of $5bn once on the market, but this target could be harder to reach now, as Novartis has filed its rival SP1 targeting drug Mayzent(siponimod) in the meantime.
Novartis: pipeline will generate 60 filings in three years

Those are headed by Mayzent (siponimod) – due to launch in the first quarter of 2019 – which it says is the “first and only drug proven to delay progression” in patients with

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow
Tackling a formidable foe

Novartis has announced positive phase III trial data for siponimod, a drug for secondary progressive MS, which reduced the risk of a patient’s disability worsening by 21% after three months

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Client Services Director- Flexible Working: Negotiable

Account Manager – Healthcare advertising: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Events Executive: DOE

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer: Competitive salary plus benefits

Subscribe to our email news alerts

PMHub

Add my company

Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...